Cargando…
Aberrant DNA methylation in cervical Carcinogenesis
Persistent infection with high-risk types of human papillomavirus(HPV) is known to cause cervical cancer; however, additional genetic and epigenetic alterations are required for progression from precancerous disease to invasive cancer. DNA methylation is an early and frequent molecular alteration in...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845585/ https://www.ncbi.nlm.nih.gov/pubmed/22943599 http://dx.doi.org/10.5732/cjc.012.10033 |
_version_ | 1782293330814566400 |
---|---|
author | Yang, Hui-Juan |
author_facet | Yang, Hui-Juan |
author_sort | Yang, Hui-Juan |
collection | PubMed |
description | Persistent infection with high-risk types of human papillomavirus(HPV) is known to cause cervical cancer; however, additional genetic and epigenetic alterations are required for progression from precancerous disease to invasive cancer. DNA methylation is an early and frequent molecular alteration in cervical Carcinogenesis. In this review, we summarize DNA methylation within the HPV genome and human genome and identify its clinical implications. Methylation of the HPV long control region (LCR) and L1 gene is common during cervical Carcinogenesis and increases with the severity of the cervical neoplasm. The L1 gene of HPV16 and HPV18 is consistently hypermethylated in invasive cervical cancers and can potentially be used as a clinical marker of cancer progression. Moreover, promoters of tumor suppressor genes (TSGs) involved in many cellular pathways are methylated in cervical precursors and invasive cancers. Some are associated with squamous cell carcinomas, and others are associated with adenocarcinomas. Identification of methylated TSGs in Pap smear could be an adjuvant test in cervical cancer screening for triage of women with high-risk HPV, atypical squamous cells of undetermined significance, or low grade squamous intraepithelial lesion (LSIL). However, consistent panels must be validated for this approach to be translated to the clinic. Furthermore, reversion of methylated TSGs using demethylating drugs may be an alternative anticancer treatment, but demethylating drugs without toxic carcinogenic and mutagenic properties must be identified and validated. |
format | Online Article Text |
id | pubmed-3845585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Sun Yat-sen University Cancer Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-38455852013-12-11 Aberrant DNA methylation in cervical Carcinogenesis Yang, Hui-Juan Chin J Cancer Review Persistent infection with high-risk types of human papillomavirus(HPV) is known to cause cervical cancer; however, additional genetic and epigenetic alterations are required for progression from precancerous disease to invasive cancer. DNA methylation is an early and frequent molecular alteration in cervical Carcinogenesis. In this review, we summarize DNA methylation within the HPV genome and human genome and identify its clinical implications. Methylation of the HPV long control region (LCR) and L1 gene is common during cervical Carcinogenesis and increases with the severity of the cervical neoplasm. The L1 gene of HPV16 and HPV18 is consistently hypermethylated in invasive cervical cancers and can potentially be used as a clinical marker of cancer progression. Moreover, promoters of tumor suppressor genes (TSGs) involved in many cellular pathways are methylated in cervical precursors and invasive cancers. Some are associated with squamous cell carcinomas, and others are associated with adenocarcinomas. Identification of methylated TSGs in Pap smear could be an adjuvant test in cervical cancer screening for triage of women with high-risk HPV, atypical squamous cells of undetermined significance, or low grade squamous intraepithelial lesion (LSIL). However, consistent panels must be validated for this approach to be translated to the clinic. Furthermore, reversion of methylated TSGs using demethylating drugs may be an alternative anticancer treatment, but demethylating drugs without toxic carcinogenic and mutagenic properties must be identified and validated. Sun Yat-sen University Cancer Center 2013-01 /pmc/articles/PMC3845585/ /pubmed/22943599 http://dx.doi.org/10.5732/cjc.012.10033 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission. |
spellingShingle | Review Yang, Hui-Juan Aberrant DNA methylation in cervical Carcinogenesis |
title | Aberrant DNA methylation in cervical Carcinogenesis |
title_full | Aberrant DNA methylation in cervical Carcinogenesis |
title_fullStr | Aberrant DNA methylation in cervical Carcinogenesis |
title_full_unstemmed | Aberrant DNA methylation in cervical Carcinogenesis |
title_short | Aberrant DNA methylation in cervical Carcinogenesis |
title_sort | aberrant dna methylation in cervical carcinogenesis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845585/ https://www.ncbi.nlm.nih.gov/pubmed/22943599 http://dx.doi.org/10.5732/cjc.012.10033 |
work_keys_str_mv | AT yanghuijuan aberrantdnamethylationincervicalcarcinogenesis |